{"id":400878,"date":"2020-12-16T08:33:30","date_gmt":"2020-12-16T13:33:30","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=400878"},"modified":"2020-12-16T08:33:30","modified_gmt":"2020-12-16T13:33:30","slug":"investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/","title":{"rendered":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco"},"content":{"rendered":"<div class=\"mw_release\">\n<p>LOS ANGELES, Dec.  16, 2020  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JC2kDvgtkgQ9FejWnoT71nk8sFozBEea2ytLFxO5n1xqTIam2ugZW8wrYo2pTQ7-awZg7CmcGB9BLr2CqYBknA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a> \u2014 <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JC2kDvgtkgQ9FejWnoT71rX2dZ1-nNFkhOsEBTBB1VpUgSWovl6ioZU2hYF-3hACG8evLS4mTrfhUaRAmIbcr6DUmMW1dO7Z5aK2BGaTino=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a> (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, chairman and CEO of <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VERi_CzcGAsehU9fpKxQdYvZ9ufAFTdR2GuKGJy8kjsIo5MYWPBq9ogqZFxfxOrecC4FB_RR0K6ZqGpyijud8nvZi8icL9iwoJMF1gIFyBJDD54FVpLzCG-9yw9Oz9n7ZRFF2mau-wmFo-OnFnm_CULKIjdmQdnRoHxy9ZtQO21lxUaRnNInIM77zZGgeAQm\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">CNS Pharmaceuticals Inc. (NASDAQ: CNSP)<\/a>, recently appeared on the \u201cWant Money Got Money\u201d podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world\u2019s most brilliant and interesting startup founders and investors.<\/p>\n<p>The podcast, hosted by author, founder, speaker and CEO Sam Kamani, is available for on-demand listening at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zwfY79QbNqY00VMRspJL8x0wM2CLHWIqRNSz-S7pnPLvR3HZ_GCzbHpG9ZmEcPXaz-JNOKw0ow7leNzTW6Ikfw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WB2vZcy_sTmEH7rauVzFOpR4napuutG5es6THm3KLSHmovlIX9X82HsrqFljuugXf5sc0p2vUWXIg3LVz4X4oQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">s<\/a><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WJ6RQCS5xWV92k35WJ2K4mXluu7a8M4980PLirMonPHyxlJYBGXH9ZoZ_cN3seFGEt9jGtXMjltKj0qBNWVe92_uwck-V6toQLNMrWnX6v0=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">amkamani.buzzsprout.com<\/a>.<\/p>\n<p>During the interview, Climaco discussed the research of CNS Pharmaceuticals founder <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7dMNdmrN4dfQCldl-KvjKHIXNUKeJvWzpVhS5dSKSCeyANM5-ZJzp2EMyTinQrQwHCNXUjG7Op-MRFI545FTz-OTpfb4DOaHglce2fvELo8=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Dr. Waldemar Priebe<\/a> into the treatment of glioblastoma multiforme (\u201cGBM\u201d), an aggressive and incurable form of brain cancer. He also provided an overview of the company\u2019s lead drug candidate, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8otKOYix4F5nCpUPS2C0Hcngoi9Bm5UNic0R5iCTb9VTnFGPC5HSTo_7IQvln_aiFJOAG_fey07FzzqUOL31iw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Berubicin<\/a>, which is proposed for the treatment of GBM. Berubicin has been evaluated in a Phase I clinical trial, in which 44% of patients experienced a clinical benefit of stable disease or better, including one patient who experienced a durable complete response and remains cancer free 14 years after treatment. CNS has applied to the U.S. Food and Drug Administration to begin a Phase II clinical trial and expects to begin enrolling patients in this trial in the first quarter of 2021.<\/p>\n<p>\u201cDr. Priebe specializes in modifying chemotherapy molecules to do things they don\u2019t normally do. He has taken a tried-and-true class of drugs called anthracyclines and made them cross the blood-brain barrier. These drugs historically have been very effective at killing cancer cells, but, because they have not crossed the blood-brain barrier, they have essentially been useless for central nervous system and brain cancers that are primary or metastatic,\u201d Climaco said.<\/p>\n<p>\u201cGlioblastoma is the worst, most aggressive form of primary brain cancer. It\u2019s a horrible disease, because there are few symptoms, there\u2019s almost no effective treatment, and, very sadly, you\u2019re probably going to die soon. The average life expectancy for a glioblastoma patient is 14-16 months.\u201d<\/p>\n<p>\u201cBerubicin looks and acts and kills cancer cells just like every other anthracycline, but the secret sauce is that it gets into the brain. What Dr. Priebe did was address a very defined and, in the grand scheme, a small innovation, but it\u2019s an absolutely critical innovation for the application of this type of drug to this type of cancer. We are laser-focused on designing the best possible study for this drug in the best environment with the best patients. With our partner in Europe, we\u2019re expecting to test almost 300 patients over the next couple of years.\u201d<\/p>\n<p>During the interview, Climaco also discussed the slow progress in treatments for glioblastoma and the potential of Berubicin to profoundly change the prognosis for GBM patients worldwide. In addition, he offers insight into his own professional background working with early-stage medical innovators.<\/p>\n<p>Learn more by listening to the full podcast at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zwfY79QbNqY00VMRspJL87n6vgClH9au-4t0aqHk97yiPSAyVqDg0VzY-w-0knN1iFGp2gECFEOPjjrP-7kNDt0JjiBnp8QKAIOCECEEtDkTiU-ZJkJvJq90igu1g4og\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/samkamani.buzzsprout.com<\/a>.<\/p>\n<p>\n        <strong>About CNS Pharmaceuticals Inc.<\/strong>\n      <\/p>\n<p>CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial, the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.<\/p>\n<p>For more information, visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7OWzFkWO2rBUj8epiP7AIYeyeKPpaiDeL28sw9BZAtV0AhKTHxRFgosSX1yCybJND0qtM_hoOEYXo23hL-hmWWOmYvJxliMgkNgXoERcYaE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.cnspharma.com<\/a>.<\/p>\n<p>\n        <strong>About InvestorBrandNetwork<\/strong>\n      <\/p>\n<p>The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JC2kDvgtkgQ9FejWnoT71qF-9QfooLyyX736y4aGyxC6GFvV1P_sY1GrvQ7LXGT9nx5UZbkLDPYFjwhQ6fR9WqP75SbvcktxwMP3Juu8uw5p6DqKM5AaZnDTZselH-r8\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorBrandNetwork<\/a> (\u201cIBN\u201d) consists of financial brands introduced to the investment public over the course of 15+ years. With IBN, we have amassed a collective audience of millions of social media followers. These distinctive investor brands aim to fulfill the unique needs of a growing base of client-partners. IBN will continue to expand our branded network of highly influential properties, leveraging the knowledge and energy of specialized teams of experts to serve our increasingly diversified list of clients.<\/p>\n<p>Through <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ePEcQlSkJQH5QL0o94B5MvuoWh0w-12dMsC27CoFmTMIZa5WJ_ML5A3A9iZKpmVzsi_rwCkoBDLQtUSh_rwtV-tCd3sMog8aexOEWGgUBLQ=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">NetworkNewsWire<\/a> (\u201cNNW\u201d) and its affiliate brands, IBN provides: (1) access to a network of wire solutions via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JC2kDvgtkgQ9FejWnoT71kHAU2A3fe9nfpjtZGnGbkrZZj5xCjOwHVXVFpvoeD75eDeAgSsHLy5lElPcPshd62aEttJZLvqTlR4EtB95p3w=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">InvestorWire<\/a> to reach all target markets, industries and demographics in the most effective manner possible; (2) article and editorial syndication to 5,000+ news outlets; (3) enhanced press release solutions to ensure maximum impact; (4) full-scale distribution to a growing social media audience; (5) a full array of corporate communications solutions; and (6) a total news coverage solution.<\/p>\n<p>For more information on IBN, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zwfY79QbNqY00VMRspJL89Wb2MpwhKWysx47KA-Wsv8Th-q8KSo6seJLOChZnn5LCJr_A2Dt5EvZ2uxkHeWIU6mC1aKrokG_6jVw9qJJkJYCwZ8Wot9uMfLfuTAX928Mv240jkf5z7UM5REMiXUrtA==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/www.InvestorBrandNetwork.com<\/a>.<\/p>\n<p>Please see full terms of use and disclaimers on the InvestorBrandNetwork website, applicable to all content provided by IBN wherever published or re-published: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=zwfY79QbNqY00VMRspJL8-Wm96JnRDI65NjudxV6wbY1uhAEqDfnr8HJkX3bFJNZZUxYFQlIVsnFBSwknNUd0i-_qB__EUMOLBk4YKSsKyg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">https:\/\/IBN.fm\/Disclaimer<\/a><\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company\u2019s SEC filings. These risks and uncertainties could cause the company\u2019s actual results to differ materially from those indicated in the forward-looking statements.<\/p>\n<p>\n        <strong>Corporate Communications<\/strong>\n      <\/p>\n<p>InvestorBrandNetwork (IBN)<br \/>Los Angeles, California<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C3QBX9UsLYUoilqWF5VOW3zgDC1Fojph5My0OaCOs6lMHIyUVrMFxI5dHvnRWzE1lQLXtVzEJ5iKB0VE04znTNlr5sjM8Poi7NWPIGhroZ8TSAbeYAXNVWfwKQ3ofh3S\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.InvestorBrandNetwork.com<\/a><br \/>310.299.1717 Office<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kG3kot3nMJmZd4p1L9c4TdlgS_2JJRw_b6l4TMLA07PTuQeSGDqkOOgss4ALSAclA7kAFrmg8_NrmHqINoJlEiMrxhsFCQ-5xspvxR68WEEKGBWJ-jERBmAxdWInErbb\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">Editor@InvestorBrandNetwork.com<\/a><\/p>\n<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3213c6ca-24c5-4298-bc59-037b5e67109a\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2014 InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the \u201cWant Money Got Money\u201d podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world\u2019s most brilliant and interesting startup founders and investors. The podcast, hosted by author, founder, speaker and CEO Sam Kamani, is available for on-demand listening at https:\/\/samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (\u201cGBM\u201d), an aggressive and incurable form of brain cancer. He also &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-400878","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2014 InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the \u201cWant Money Got Money\u201d podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world\u2019s most brilliant and interesting startup founders and investors. The podcast, hosted by author, founder, speaker and CEO Sam Kamani, is available for on-demand listening at https:\/\/samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (\u201cGBM\u201d), an aggressive and incurable form of brain cancer. He also &hellip; Continue reading &quot;InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-16T13:33:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco\",\"datePublished\":\"2020-12-16T13:33:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/\"},\"wordCount\":1016,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/\",\"name\":\"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\",\"datePublished\":\"2020-12-16T13:33:30+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/","og_locale":"en_US","og_type":"article","og_title":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk","og_description":"LOS ANGELES, Dec. 16, 2020 (GLOBE NEWSWIRE) &#8212; via InvestorWire \u2014 InvestorBrandNetwork (\u201cIBN\u201d), a multifaceted financial news and publishing company for private and public entities, today announces that John Climaco, chairman and CEO of CNS Pharmaceuticals Inc. (NASDAQ: CNSP), recently appeared on the \u201cWant Money Got Money\u201d podcast, a series that helps entrepreneurs learn from the stories, secrets and skills of the world\u2019s most brilliant and interesting startup founders and investors. The podcast, hosted by author, founder, speaker and CEO Sam Kamani, is available for on-demand listening at https:\/\/samkamani.buzzsprout.com. During the interview, Climaco discussed the research of CNS Pharmaceuticals founder Dr. Waldemar Priebe into the treatment of glioblastoma multiforme (\u201cGBM\u201d), an aggressive and incurable form of brain cancer. He also &hellip; Continue reading \"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-16T13:33:30+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco","datePublished":"2020-12-16T13:33:30+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/"},"wordCount":1016,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/","name":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=","datePublished":"2020-12-16T13:33:30+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODExMzAxOCMzODgzNzk0IzIwODg3OTk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/investorbrandnetwork-announces-want-money-got-money-podcast-with-cns-pharmaceuticals-inc-chairman-and-ceo-john-climaco\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"InvestorBrandNetwork Announces \u2018Want Money Got Money\u2019 Podcast with CNS Pharmaceuticals Inc. Chairman and CEO John Climaco"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400878","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=400878"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/400878\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=400878"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=400878"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=400878"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}